Telo Therapeutics, Inc. Information

As an oncology therapeutics company, Telo Therapeutics’ mission is to dramatically improve survival and well-being in cancer patients who have run out of treatment options. Telo Therapeutics is focused on developing orally bioavailable next-generation inhibitors of nuclear transport, a critical nexus among many cancer cell signaling pathways. Our Development candidate, TSM74, is a novel targeted protein degrader of XPO1, a clinically validated oncology target relevant to a wide-range of solid and hematological cancers. TSM74 has a dramatically improved safety profile compared to existing toxic covalent inhibitors, leading to rapid tumor regressions and complete tumor removal across multiple preclinical cancer models.